INSIGHTS: AMERICAN PHARMACEUTICAL REVIEW'S EDITORIAL ADVISORY BOARD COLUMN

摘要

Orally disintegrating tablets (ODT) or sublingual technologies have drawn attention in the industry as a promising approach to deliver drugs in iife cycle management to a wide range of the patient population [1-6]. Those technologies are also aimed at patients incapable of swallowing pills, especially in pediatric and geriatric populations [7], The criteria for rapid dissolution and onset of active ingredients in an ODT dosage depends on the performances of individual excipients which must qualify 3 unique criteria: (i) hydrophilic in nature, (ii) dissolves quickly with good mouth feel, and (iii) is highly compressible. Identifying such excipients and/ or technologies to meet these criteria could be challenging, especially to overcome the drug's loading and stability.